OncoSTING Overview

  • Founded
  • 2018

  • Status
  • Private

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $256K

  • Investors
  • 4

OncoSTING General Information


Developer of a biopharma therapy designed to cure bladder cancer. The company's therapy work by combining the potency of standard BCG immunotherapy with long-lived delivery of potent STING agonists, enabling doctors to cure bladder cancer with reduced adverse events associated with traditional BCG.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Industries
Drug Discovery
Primary Office
  • 17 South Chester Street
  • Baltimore, MD 21231
  • United States

OncoSTING Timeline

Financing Round

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

OncoSTING Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Grant 01-Jun-2022 $256K 00000 Completed Generating Revenue
4. Grant 08-Jul-2019 00000 00000 Completed Generating Revenue
3. Early Stage VC 02-Jul-2019 00000 00000 Completed Generating Revenue
2. Accelerator/Incubator 28-Jun-2019 Completed Generating Revenue
1. Grant 23-Feb-2018 Completed Generating Revenue
To view OncoSTING’s complete valuation and funding history, request access »

OncoSTING Executive Team (4)

Name Title Board Seat Contact Info
Todd Wallach Chief Business Officer
Trinity Bivalacqua Ph.D Co-Founder
William Bishai Ph.D Co-Founder
You’re viewing 3 of 4 executive team members. Get the full list »

OncoSTING Board Members (1)

Name Representing Role Since
Ambaw Bellete OncoSTING Chairman 000 0000
To view OncoSTING’s complete board members history, request access »

OncoSTING Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
National Institutes of Health Government 000 0000 000000 0
National Science Foundation Government 000 0000 000000 0
Johns Hopkins University Endowment Limited Partner 000 0000 000000 0
TEDCO Venture Capital Minority 000 0000 000000 0
To view OncoSTING’s complete investors history, request access »